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The  speed  of kill  of afoxolaner  against  experimental  infestations  by  Ctenocephalides  felis was
evaluated after oral  administration  of  afoxolaner  in  a soft  chew  (NEXGARD®)  at  a  dose  to
achieve 2.5  mg/kg  bodyweight.  Forty  beagles  were  allocated  to  two  treatment  groups.  Dogs
in  Treatment  Group  1 were  untreated  controls.  Dogs  in  Treatment  Group  2 were  treated
on Day-0  with  afoxolaner,  according  to  their  pre-treatment  bodyweight.  All dogs  were
infested  with  approximately  100  C.  felis  on  Day-1.  Live  ﬂeas  were counted  upon  removal  at
5 time  points  after  treatment  (i.e., 2, 4, 8, 12  and 24  h  after  treatment).  For  each  time  point,
counts  were  performed  on  4 dogs  from  each  of the  treated  and  the  untreated  groups.  Early
curative  ﬂea  killing  efﬁcacy  was  evaluated  with  respect  to the  untreated  control  group.  The
afoxolaner  treated  group  had signiﬁcantly  fewer  ﬂeas  than  the  untreated  control  group  at
8,  12,  and  24  h  (p  <  0.001).  The  percent  efﬁcacies  of orally  administered  afoxolaner  were
15.0%,  87.8%,  99.5%,  100.0%,  and  100.0%  at 2, 4, 8, 12,  and 24  h, respectively.  In this  study,
afoxolaner  began  killing  ﬂeas  by 2 h  after  treatment  with  increasing  efﬁcacy  at subsequent
time  points  and  had >99.5%  efﬁcacy  at 8, 12,  and  24  h  after  treatment  demonstrating  an
early  onset  of  action.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The burden of ﬂeas is recognized for decades in com-
panion animals worldwide. The cat ﬂea, Ctenocephalides
felis felis, is the predominant species found on dogs and
cats (Beugnet and Franc, 2012; Dryden and Rust, 1994).
Given the pathogenic and zoonotic potential and the
high prevalence of ﬂeas (Beugnet and Marie, 2009; Azad
et al., 1997; Beugnet, 2013; Just et al., 2008), their con-
trol represents a key achievement for the health of cats
and dogs. The optimal ﬂea control program includes the
rapid elimination of established ﬂea infestations while
providing a long lasting protection from a continuous
challenge and at the same time demonstrating a high
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licenses/by-nc-nd/3.0/).degree of efﬁcacy. It also requires the quick elimination
of adult ﬂeas prior to egg production (Carlotti and Jacobs,
2000).
Afoxolaner is a recently identiﬁed insecticide-acaricide
molecule belonging to the isoxazoline class that has
demonstrated excellent effectiveness against ﬂeas and
ticks in dogs (Hunter et al., 2014; Dumont, 2014; Mitchell
et al., 2014; Kunkle et al., 2014). It is formulated as an oral
soft chewable and it acts systematically in the dog against
ﬂeas (Letendre et al., 2014). Afoxolaner is a speciﬁc and
novel blocker of ligand-gated chloride channels in insects,
resulting in hyperexcitation and rapid death of the arthro-
pods (Shoop et al., 2014).We herein provide additional data on the efﬁcacy of
afoxolaner against C. felis. The study was  conducted to
determine the curative speed of kill against existing adult
ﬂea infestations on dogs.
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B.N. Kunkle et al. / Veterinary Parasitology 201 (2014) 204–206 205
Table  1
Percent curative efﬁcacy of oral formulation of afoxolaner administered to dogs against existing C. felis ﬂea infestations at minimum therapeutic dose of
2.5  mg/kg.
Time after treatment (h) N Untreated control
geometric mean ﬂea count
N Treated oral
geometric mean ﬂea count
Percent
efﬁcacy
p-Value
2.0 4 79.2 4 67.4 15.0 0.209
4.0  4 74.3 4 9.0 87.8 0.064
8.0  4 65.3 4 0.3 99.5 < .001
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. Materials and methods
.1. Animals
Forty-four healthy beagles of both sexes (22 males
nd 22 females), 13.8–37.5 months of age, and weighed
.05–14.75 kg were included in the study. The protocol of
he study was reviewed and approved by the Merial Institu-
ional Animal Care and Use Committee (IACUC). Dogs were
andled with due regard for their welfare (USDA, 2008).
ll animals were housed individually. All dogs received
ommercial food, once daily, in a sufﬁcient amount to
aintain body weight appropriate for the breed, and water
as provided ad libitum. The dogs were not treated with
ctoparasiticides (either topical or systemic) within three
onths prior to the start of the study. Dogs enrolled in the
tudies underwent a full physical examination by a veteri-
arian on Day-7 and were examined once daily for health
bservations.
. Experimental study designs
The study design was in accordance with the World
ssociation for the Advancement of Veterinary Parasito-
ogy (WAAVP) guidelines for evaluating the efﬁcacy of
arasiticides for the treatment, prevention and control of
ea and tick infestation on dogs and cats (Marchiondo
t al., 2013), and was conducted in accordance with Good
linical Practices as described in International Cooperation
n Harmonization of Technical Requirements for Registra-
ion of Veterinary Medicinal Products (VICH) guideline GL9
EMEA, 2000).
The study was a blinded, negative controlled study
sing a randomized block design with blocks of 4 dogs
ased on the ﬂea counts obtained after preliminary infes-
ations on Day-6 for allocation purposes. The 4 dogs with
he lowest pre-infestation ﬂea counts were not allocated.
he C. felis strain used for infestations was a U.S. strain
f ﬂeas that has been maintained for approximately 6
ears from ﬂeas collected in Oklahoma (Ecto Services,
nc.).
Each infestation (Day-6 for allocation purpose and Day-
 for treatment evaluation), was performed by placing
pproximately 100 (±5) C. felis (equal numbers of male and
emale adult ﬂeas) along the dorsum or the dorso-sacral
rea of each dog.
Within each block, the dogs were randomized to one of
he 10 counting time-by-treatment combinations as fol-
ows: 2 h: untreated control and treated; 4 h: untreated4 0.0 100.0 < 0.001
4 0.0 100.0 < 0.001
control and treated; 8 h: untreated control and treated;
12 h: untreated control and treated; 24 h: untreated control
and treated.
Dogs in the treated group were dosed orally on Day-0
with the appropriate chewable tablets containing afox-
olaner. Four sizes of chews were available: 0.5 g, 1.25 g,
3 g and 6 g, containing respectively 11.3 mg,  28.3 mg,
68 mg  and 136 mg  of afoxolaner. The dose range was
2.5–2.97 mg/kg using a combination of the chews in order
to be as close as possible to the minimum therapeutic dose
of 2.5 mg/kg. Dogs were observed prior to treatment and
hourly (±30 min) for 4 h post-treatment. At 2, 4, 8, 12 and
24 h after oral treatment depending on the groups, ani-
mals were combed and ﬂeas were removed, counted and
categorized as dead or alive.
4. Data analysis
The ﬂea counts were transformed to the natural log-
arithm of (count + 1) for calculation of geometric means
by treatment group at each time point. Percent efﬁcacy
of the treated group with respect to the control group
was calculated using the formula [(C − T)/C] × 100, where
C = geometric mean for the control group and T = geometric
mean for the treated group for each time point. The
log-counts of the treated group were compared to the
log-counts of the untreated control group using an F-test
adjusted for the allocation blocks used to randomize the
animals to the treatment groups at each time point sepa-
rately. The Mixed procedure in SAS® version 9.1.3 was used
for the analysis, with treatment group listed as a ﬁxed effect
and the allocation blocks listed as a random effect. All com-
parisons were made using the (two-sided) 5% signiﬁcance
level.
5. Results
No adverse events related to the administration of afox-
olaner soft chewables were observed during the study.
The onset of efﬁcacy of orally administrated afoxolaner
on pre-existing ﬂea infestations are presented in Table 1.
The percent efﬁcacies for the treated groups were 15%,
87.8%, 99.5% 100%, and 100% at 2, 4, 8, 12 and 24 h,
respectively. The treated dogs had fewer ﬂeas than the
untreated control group at 4 h and signiﬁcantly fewer at
all following time points (p ≤ 0.001). In this study, the
oral administration of afoxolaner provided a signiﬁcant
reduction in the ﬂea burden by 4 h after treatment and
y Parasi206 B.N. Kunkle et al. / Veterinar
reached a high ﬂea killing activity by 8 h after administra-
tion.
6. Discussion
This study demonstrated that afoxolaner administered
in a beef-ﬂavored soft chew at the minimum therapeu-
tic dose of 2.5 mg/kg, provided a rapid adulticidal efﬁcacy
(87.8% within 4 h compared to the control dogs). The efﬁ-
cacy of afoxolaner compared to control dogs increased to
99.5% at 8 h post-treatment and 100% at 12 and 24 h post-
treatment.
The efﬁcacy results correlate with the pharmacoki-
netic data that indicates that following administration
of 2.5 mg/kg to dogs, afoxolaner plasma concentrations
increased rapidly to peak within 2–6 h. The ﬂea and tick
efﬁcacies are directly related to the rapid absorption of
afoxolaner and a plasma peak reaching the lethal concen-
tration (LC90) in the blood, around 23 ng/mL for ﬂeas and
100 ng/mL for ticks (Letendre et al., 2014; Shoop et al.,
2014). The speed of kill is also be related to the speed
and number of ﬂeas taking a blood meal soon after the
oral dosing of the dogs. In addition, the long terminal
plasma half-life of approximately two weeks (12.8 ± 5.6
days) results in an average afoxolaner plasma concentra-
tion above the effective concentration for efﬁcacy against
ﬂeas for a duration of one month (Letendre et al., 2014).
This long lasting efﬁcacy has been conﬁrmed in several
experimental studies conducted on C. canis and C. felis ﬂeas
(Dumont, 2014; Hunter et al., 2014).
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